Underlining Exelixis Bright Future

Exelixis Bright Future
Exelixis Fourth Quarter and Full Year 2020 Financial Results  
Exelixis (EXEL) announced its preliminary unaudited financial results for the Fourth Quarter and Full Year 2020. It also provided financial guidance for the full year 2021 and delivered an update on its business.

With regard to Exelixis most important franchise, cabozantinib, the product’s net revenues reached $200 million in the . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.